CollPlant investors approve EGM proposal at meeting

CollPlant Biotechnologies Ltd. reported that it held an Extraordinary General Meeting of Shareholders on July 29, 2026.

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. reported that it held an Extraordinary General Meeting of Shareholders on July 29, 2026. Shareholders approved the proposal presented at the meeting, which had been described in the company’s Notice of Extraordinary General Meeting of Shareholders dated July 7, 2026.

The report is incorporated by reference into CollPlant’s existing Registration Statements on Form S-8 and Form F-3, becoming part of those registration statements from the submission date, unless later superseded.

Key Figures

Extraordinary General Meeting date: July 29, 2026 Notice of Meeting date: July 7, 2026

2 metrics

Extraordinary General Meeting date July 29, 2026 Date the Extraordinary General Meeting of Shareholders was held

Notice of Meeting date July 7, 2026 Date of the Notice of Extraordinary General Meeting describing the proposal

Key Terms

Form 6-K, foreign private issuer, Extraordinary General Meeting of Shareholders, Registration Statements on Form S-8, +1 more

5 terms

Form 6-K regulatory

"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Extraordinary General Meeting of Shareholders regulatory

"held an Extraordinary General Meeting of Shareholders (the “Meeting”)"

A meeting called by a company outside its regular annual meeting to address urgent or special matters that cannot wait until the next scheduled meeting. Investors attend or vote to decide on actions such as major deals, leadership changes, capital-raising, or rule changes; think of it as an emergency board meeting where shareholders have a direct say and the outcomes can quickly change a company’s strategy, ownership stakes, or financial prospects.

Registration Statements on Form S-8 regulatory

"incorporated by reference into the registrant’s Registration Statements on Form S-8"

Registration Statements on Form F-3 regulatory

"incorporated by reference into the registrant’s Registration Statements on Form F-3"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CollPlant Biotechnologies (CLGN) report in its July 2026 Form 6-K?

CollPlant Biotechnologies reported that it held an Extraordinary General Meeting of Shareholders on July 29, 2026, where shareholders approved the proposal presented. The approved proposal had been described in a Notice of Extraordinary General Meeting dated July 7, 2026.

When was CollPlant Biotechnologies' (CLGN) Extraordinary General Meeting held?

The Extraordinary General Meeting of Shareholders was held on July 29, 2026. This meeting followed a Notice of Extraordinary General Meeting distributed on July 7, 2026, which described the proposal later approved by the company’s shareholders at the meeting.

What proposal did CollPlant Biotechnologies (CLGN) shareholders approve?

Shareholders approved the single proposal presented at the Extraordinary General Meeting. The company states that this proposal was described in its Notice of Extraordinary General Meeting of Shareholders dated July 7, 2026, which outlined the matter submitted for shareholder approval.

How does this CollPlant Biotechnologies (CLGN) report relate to its registration statements?

The report is incorporated by reference into CollPlant’s Registration Statements on Form S-8 and Form F-3. This means the information from the report becomes part of those registration statements from the submission date, unless later superseded by other reports.

Which SEC forms are referenced in CollPlant Biotechnologies' (CLGN) July 2026 report?

The company references existing Registration Statements on Form S-8 and Form F-3. The July 2026 report is incorporated by reference into multiple S-8 registration statements and several F-3 registration statements identified by their respective file numbers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 07:28 AM Accepted by SEC EDGAR 07/29/2026 - 07:27 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

This Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163, 333-248479, 333-263842, 333-271320 and 333-279791) and Form F-3 (File No. 333-238731, 333-292640 and 333-297347), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On July 29, 2026, CollPlant Biotechnologies Ltd. (the “Company”) held an Extraordinary General Meeting of Shareholders (the “Meeting”). At the Meeting, the Company’s shareholders approved the proposal brought before the shareholders, in accordance with the majority required for such proposal. This proposal was described in the Company’s Notice of Extraordinary General Meeting of Shareholders, dated July 7, 2026, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on July 7, 2026.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.
Date: July 29, 2026	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer

2